Combination blood pressure lowering in the presence or absence of background statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE Trials
dc.rights.license | open | en_US |
dc.contributor.author | WANG, Nelson | |
dc.contributor.author | HARRIS, Katie | |
dc.contributor.author | CHALMERS, John | |
dc.contributor.author | HARRAP, Stephen | |
dc.contributor.author | MANCIA, Giuseppe | |
dc.contributor.author | MARRE, Michel | |
dc.contributor.author | POULTER, Neil | |
hal.structure.identifier | Bordeaux population health [BPH] | |
dc.contributor.author | TZOURIO, Christophe
IDREF: 69829209 | |
dc.contributor.author | WILLIAMS, Bryan | |
dc.contributor.author | ZOUNGAS, Sophia | |
dc.contributor.author | WOODWARD, Mark | |
dc.contributor.author | RODGERS, Anthony | |
dc.date.accessioned | 2021-06-30T10:17:33Z | |
dc.date.available | 2021-06-30T10:17:33Z | |
dc.date.issued | 2021-04-20 | |
dc.identifier.issn | 1473-5598 (Electronic) 0263-6352 (Linking) | en_US |
dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/94939 | |
dc.description.abstractEn | OBJECTIVES: To assess the effects of combination BP lowering on cardiovascular events and mortality in the presence of aspirin and/or statin therapy in a combined analysis of the ADVANCE and PROGRESS trials. METHODS: We conducted an analysis of 14 682 participants allocated combination therapy with perindopril and indapamide or placebo followed up for a mean of 4.2 years. Participants were stratified into four groups defined by background use of medications at baseline: statin, aspirin, both or neither. Linear mixed effect models were used to assess differences in BP and Cox proportional hazard models were used to estimate the risks of major cardiovascular events, all-cause mortality and treatment discontinuation. RESULTS: At baseline, 14% of patients were on both aspirin and statin, 35% on aspirin, 9% on statins and 42% on neither aspirin/statins. Compared with placebo, combination BP therapy reduced mean SBP by 5.7 mmHg in ADVANCE and 12.1 mmHg in PROGRESS, with no difference (P > 0.447) between patients by baseline use of aspirin/statin. Combination BP therapy reduced the risk of major cardiovascular events (hazard ratio 0.78, 95% CI 0.71-0.86), with no significant difference (P = 0.600) between aspirin/statin subgroups. Rates of treatment discontinuation were similar with combination BP therapy compared with placebo (18.4 versus 18%), with no evidence of difference across the subgroups (P = 0.340). CONCLUSION: BP lowering with perindopril and indapamide reduces the risk of major cardiovascular events independent of baseline use of aspirin and/or statins. | |
dc.language.iso | EN | en_US |
dc.title.en | Combination blood pressure lowering in the presence or absence of background statin and aspirin therapy: a combined analysis of PROGRESS and ADVANCE Trials | |
dc.type | Article de revue | en_US |
dc.identifier.doi | 10.1097/hjh.0000000000002862 | en_US |
dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
dc.identifier.pubmed | 33883461 | en_US |
bordeaux.journal | Journal of Hypertension | en_US |
bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
bordeaux.institution | Université de Bordeaux | en_US |
bordeaux.institution | INSERM | en_US |
bordeaux.team | HEALTHY_BPH | en_US |
bordeaux.peerReviewed | oui | en_US |
bordeaux.inpress | non | en_US |
hal.identifier | hal-03274643 | |
hal.version | 1 | |
hal.date.transferred | 2021-06-30T10:17:37Z | |
hal.export | true | |
bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Hypertension&rft.date=2021-04-20&rft.eissn=1473-5598%20(Electronic)%200263-6352%20(Linking)&rft.issn=1473-5598%20(Electronic)%200263-6352%20(Linking)&rft.au=WANG,%20Nelson&HARRIS,%20Katie&CHALMERS,%20John&HARRAP,%20Stephen&MANCIA,%20Giuseppe&rft.genre=article |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |